An amino-acid switch in the BCR-ABL kinase domain modifies sensitivity to imatinib mesylate Leukemia (2005) Chronic myelogenous leukemia (CML), a clonal hematopoietic stem cell disorder, is characterized by the presence of the BCR-ABL tyrosine kinase (TK) oncogene, the product of Philadelphia (Ph) chromosome that results from a t(9;22)(q34; q11) reciprocal translocation. Imatinib mesylate (Glivec, STI571) inhibits BCR-ABL TK activity and induces specifically leukemic cell apoptosis. This drug has proved very successful for the treatment of CML when administered in the chronic phase. In contrast, in the advanced phase, remissions are less frequent and are followed by the emergence of resistance to imatinib. BCR-ABL gene amplification and mutations in the BCR-ABL kinase domain are the most frequent mechanisms of resistance. 1 Mutations causing amino-acid substitution can be classified into four groups: (i) in the imatinib binding site-like T315I mutation, (ii) in the P-loop (ATP phosphate binding loop for ATP) like G250E mutation, (iii) in the activation loop, and (iv) in the C-terminal lobe of the enzyme. [1] [2] [3] In the current study, we investigated a new mutation in the P-loop domain G250A detected in a resistant patient. An in vitro functional study was performed using G250A mutant compared to a G250E mutant already characterized and to one of the most resistant mutant T315I engineered in Baf/BCR-ABL cells.
Previously, 18 patients in late chronic phase CML and resistant to imatinib mesylate after a median time of 13 months of treatment were investigated to screen for mutations in the TK domain. For these patients, resistance was defined by the absence of cytogenetic response after 6 months of treatment, whatever the hematological response. Briefly, after extraction of total RNA from peripheral blood samples, a seminested reverse transcriptase-polymerase chain reaction (RT-PCR) was performed to amplify a 1298-bp fragment including the BCR-ABL fusion point and the ATP binding site and was followed by direct sequencing. The mutation was considered as detected only if the same mutation was detected in repeat analysis. A new G250A (substitution of a glycine by an alanine) mutation was identified in our patient's group. The patient was a 57-year-old woman diagnosed in 1987 with Ph-positive CML in chronic phase (Sokal ¼ 0.68). She underwent leukapheresis and was treated with interferon (IFN). Neither cytogenetic response nor hematological remission was achieved and evolution to accelerated phase was rapid, so she was treated by double autologous peripheral blood stem cell transplantation ( To evaluate the role of this substitution on the imatinib resistance of leukemic cells, we generated three different plasmids by site-directed mutagenesis: a wild-type (wt) BCR-ABL, a G250A mutation and a G250E mutation, from the 9.5 kb plasmid pEYK3.1 containing the complete BCR-ABL sequence with the T315I mutation (kindly provided by G Daley 2 ). Baf/ BCR-ABL cells were transfected with the different mutants, named Baf/BCR-ABL wt, Baf/BCR-ABL T315I, Baf/BCR-ABL G250E and Baf/BCR-ABL G250A, and tested for imatinib sensitivity with increasing doses of imatinib (0, 0.1, 0.5, 1, 5 and 10 mM). The viability test demonstrated that G250A nucleotide substitution conferred resistance to imatinib because 88% of cells were still alive after 4 days with 0.5 mM of imatinib. However, this resistance was moderate because 70% of cells were dead after 4 days with 1 mM of imatinib. For the Baf/BCR-ABL wt, 59% of cells were alive after 4 days with 0.5 mM of imatinib and 67% of cells were dead with 1 mM. In contrast, the Baf/BCR-ABL T315I and G250E cells were resistant to the inhibitor. Indeed, 96% of cells were still alive after 4 days of treatment with 1 mM of imatinib (data not shown). Cellular proliferation evaluated using MTS assay showed that at day 4, the dose of imatinib needed to inhibit 50% of proliferation was more than 10 mM for T315I and G250E mutants as compared to 0.5 mM for G250A and 0.1 mM for the wt (Figure 1 ). Western blot analysis demonstrated no decrease in STAT5 phosphorylation in the Baf/BCR-ABL T315I or G250E (Figure 2) . These results confirmed the resistance to imatinib observed in culture using MTS assay for G250E or T315I mutants. In contrast, STAT5 phosphorylation for Baf/BCR-ABL wt was lower than for Baf/ BCR-ABL G250A (Figure 2 ). 
Spotlight Correspondence
Imatinib has modified the treatment of CML but mechanisms of resistance have been reported. 1, 4 The estimated 2-year incidence of resistance in chronic phase to imatinib was 10% post-IFN failure. However, the appearance of mutations is the most striking phenomenon observed in resistant patients. It has been described in all clinical phases of the disease but is more frequent in the advanced phase than in the chronic phase. 5 Inhibition of the BCR-ABL TK depends on the drug concentration. In vitro studies have shown that leukemic cells respond to the treatment when the concentration of imatinib reaches 1 mM. However, clinical studies suggest that in vivo concentrations are not homogeneous throughout all tissues. Indeed, imatinib inhibition might be precluded by modifying the active drug concentration, thus accounting for the in vivo resistance observed in spite of the intermediate resistance demonstrated in vitro for the G250A mutation.
We have found a new mutation inducing intermediate resistance in response to dose escalation from a stable chronic phase disease and demonstrated in the cellular model. This 70-year-old woman is still alive in second chronic phase after more than 3 years of treatment. This case demonstrates that a small group of mutations inducing a very low level of resistance can be overcome with increasing doses of imatinib but without inducing any other mechanism of resistance. It also demonstrates that resistance level not only depends on the location of the amino acid but also on the type of substitution. Alanine has a chemical structure that is closer to the structure of glycine than to that of glutamic acid. It may be that the steric disturbance induced by alanine is lower than that induced by a glutamic acid. These amino acids located in the P-loop do not interact directly with the drug. Different amino acid substitutions at the same position leading to different levels of resistance have also been reported. 2 Corbin et al 6 also measured the IC 50 values of two mutations at T315 and found different levels of resistance for T315I and T315 V. This appears to be similar to the findings for G250E and G250A and undermines the tenet that different substitutions of T315 always lead to the same resistance level, as reported by other groups. 7 Results from previous studies have demonstrated that the T315I mutation is more resistant than G250E. 2, 8 In conclusion, this is the first report of intermediate resistance observed clinically, confirmed in vitro and correlated with slow clinical evolution in a CML patient. While the locations of mutations in the TK domain such as the P-loop are known to be important for the prognosis of the disease, this case shows that the type of mutation is also probably important for the evolution of CML under imatinib treatment. However, studies using conditional knock-in mice with PEBP2b-MYH11 have documented that while the fusion protein is critical for leukemogenesis, additional genetic events are required for the development of acute myeloblastic leukemia (AML). Recently, mutations in the class III receptor tyrosine kinase (RTK) including C-KIT and FLT3 were frequently found in patients with inv(16) AML. 2 These mutations could represent potential therapeutic targets for specific tyrosine kinase inhibitors. However, clinical efficacy of imatinib mesylate in AML patients with C-KIT mutation remains to be determined. While an approximately half of the patients with inv(16) AML generally have a favorable outcome, the treatment outcome is not
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